Ankyra Therapeutics Appoints Robert V. Tighe as Chief Scientific Officer

Ankyra Therapeutics announced the appointment of Robert V. Tighe as chief scientific officer. He brings considerable immuno-oncology drug development experience to the company and has over 20 years of industry experience. He has most recently served as Vice President of Research at TCR2 Therapeutics.

Ankyra Therapeutics is a biopharmaceutical company that focuses on developing novel treatments for autoimmune and inflammatory diseases.